
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems is currently facing uncertainty surrounding reimbursement and coding of its product due to AHA recommendations, which could possibly limit growth potential in the near term. However, long-term growth potential remains positive with the introduction of a new product cycle and underpenetrated TAM. Downside risks include potential competition and changes in reimbursement, while a guidance cut on the 1Q earnings call has caused uncertainty. This analyst has therefore downgraded INSP to a neutral rating until there is more clarity on these issues.
Bears say
Inspire Medical Systems is facing significant challenges with inventory dynamics, reimbursement changes, and competition from GLP-1 drugs, which have led to a decrease in revenue growth and a significant cut in 2026 revenue guidance. This negative outlook is supported by the company's recent PT adjustment to $50, based on lower revenue estimates and a lower multiple, as well as potential future challenges that may hinder growth and profitability. Overall, there are uncertainties surrounding Inspire's near-term growth and profitability, making the stock a risky investment at this time.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares